Patents by Inventor Simone Popp

Simone Popp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
    Publication number: 20240368266
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Application
    Filed: November 14, 2023
    Publication date: November 7, 2024
    Applicant: Universität Zürich
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
    Patent number: 11851484
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: December 26, 2023
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
    Publication number: 20210246200
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Application
    Filed: December 17, 2020
    Publication date: August 12, 2021
    Applicants: Universität Zürich
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
    Patent number: 10889643
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: January 12, 2021
    Assignee: Universität Zürich
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
    Publication number: 20190016797
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Application
    Filed: January 11, 2017
    Publication date: January 17, 2019
    Applicants: Novartis AG, Universität Zürich
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou